The UCLA Biomarker Reference Laboratory (UCLA BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA BRL. Significantly, the UCLA BRL has been highly successful having established numerous EDRN collaborations and constructed and successfully utilized tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) the utilization of our diverse and extensive infrastructure and highly skilled personnel to test, evaluate, quantify, validate and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers which are protein and/or nucleic acid in nature in tissue and/or in fluids. To this end, the Scientific Centers have extensive experience and expertise in assay performance and development for tissues (full tissue sections or 'intelligent high-density tissue microarrays), proteins (including conventional and high-throughput protemics), and nucleic acids (including expression profiles, DNA modifications or mutations, chromosomal abnormalities, and/or microRNA profiles), ii) This includes a developmental program focused on defining clinically useful tumor markers utilizing high density tissue microarray combined with a novel data-mining tool suite, iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program, iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful tumor biomarkers. The UCLA BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer Program, and the UCLA Prostate Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA086366-15
Application #
8689942
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Sorbara, Lynn R
Project Start
2000-05-16
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-1601
Ho, Melissa E; Quek, Sue-Ing; True, Lawrence D et al. (2016) Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. Oncotarget 7:15747-56
Hamilton, Nalo; Márquez-Garbán, Diana; Mah, Vei et al. (2015) Biologic roles of estrogen receptor-? and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int 2015:925703
Alavi, Mohammed; Mah, Vei; Maresh, Erin L et al. (2015) High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15:655
Tian, Yuan; Choi, Caitlin H; Li, Qing Kay et al. (2015) Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS One 10:e0121502
Hamilton, Nalo; Marquez-Garban, Diana; Mah, Vei H et al. (2015) Estrogen Receptor-? and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog 20:373-90
Tang, Jason H; Chia, David (2015) Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Crit Rev Oncog 20:357-71
Mah, Vei; Alavi, Mohammad; Márquez-Garbán, Diana C et al. (2015) Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One 10:e0127600

Showing the most recent 10 out of 45 publications